By. Shannon Westin, MDDate. October 27, 2023 In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E Phase III trial, focusing on the combination of IMFINZI® (durvalumab) and LYNPARZA® (olaparib) in advanced or recurrent endometrial cancer and its implications for patient treatment options. Dr. Shannon Westin highlights the significant impact of … Continue reading Durvalumab + olaparib 45% Reduction Disease Progression in Endometrial – ESMO 2023